Eaton Vance Management’s Neurogene NGNE Stock Holding History

Eaton Vance Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11	Closed	-$2K	–	2454
2021 Q2	$2K	Buy	+11	New	+$2.43K	﹤0.01%	2720

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Eaton Vance Management's NGNE Position: Q3 2021 in Review

Eaton Vance Management sold out of Neurogene (NGNE) in Q3 2021, closing a stake of 11 shares — an estimated $2K sold.

Eaton Vance Management first reported a position in NGNE in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 85 funds tracked by Wall St. Rank hold NGNE as of Q3 2021.

Eaton Vance Management reported no remaining Neurogene position as of Q3 2021 after selling out during the quarter.
Eaton Vance Management sold 11 Neurogene shares in Q3 2021, an estimated $2K.
Eaton Vance Management first reported a position in Neurogene in Q2 2021 and held it in 1 quarter.
Eaton Vance Management's Neurogene position peaked at $2K in Q2 2021.
85 funds tracked by Wall St. Rank held Neurogene as of Q3 2021.

Based on Eaton Vance Management's 13F filing for Q3 2021, filed 15 Nov 2021.